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Hybrid Coronary Revascularization
Promising, But Yet to Take Off
Vasileios F. Panoulas, MD, PHD,*yz Antonio Colombo, MD,*y Alberto Margonato, MD,* Francesco Maisano, MDx
ABSTRACT
Hybrid coronary revascularization (HCR) combines arterial coronary artery bypass surgery (most commonly minimally
invasive) and percutaneous coronary intervention in the treatment of a particular subset of multivessel coronary
artery disease. It was ﬁrst introduced in the mid-1990s, and aspired to bring together the “best of both worlds”:
the excellent patency rates and survival beneﬁts associated with the durable left internal mammary artery graft
to the left anterior descending artery alongside the good patency rates of drug-eluting stents, which outlive
saphenous vein grafts to non–left anterior descending vessels. Although in theory this is a very attractive revas-
cularization strategy, several years later, only one small randomized controlled trial comparing HCR with coronary
artery bypass grafting has recently emerged in the medical literature, raising concerns regarding HCR’s role and
generalizability. In the current review, we discuss HCR’s rationale, the current evidence behind it, its limitations and
procedural challenges. (J Am Coll Cardiol 2015;65:85–97) © 2015 by the American College of Cardiology
Foundation.
H ybrid coronary revascularization (HCR) wasﬁrst introduced in the mid-1990s (1) as apioneering treatment approach to multives-
sel coronary artery disease (CAD), hoping to bring
together the “best of both worlds” (2). HCR aims to re-
duce surgical trauma while preserving long-term sur-
vival and minimizing adverse cardiovascular events.
The hybrid approach includes left internal mam-
mary artery (LIMA) anastomosis to the left anterior
descending coronary artery (LAD), typically via a
minimally invasive approach, and percutaneous cor-
onary intervention (PCI) for the remaining (non-LAD)
lesions. Variations to this schema were discussed in a
recent nomenclature paper (3), including the grafting
of multiple coronary vessels (e.g., LIMA to LAD and
saphenous graft to diagonal).
THE RATIONALE FOR HCR
The rationale for HCR lies in the well-established
survival beneﬁt conferred by LIMA-to-LAD grafts
(4–6) and the use of new stent platforms (7) featuring
lower stent restenosis and thrombosis rates compared
with venous graft stenosis and occlusion rates,
respectively (8).
THE SURVIVAL BENEFIT OF A SURGICAL LIMA-TO-LAD
GRAFT. A unique conduit, the LIMA powerfully
resists thrombosis and atherosclerosis (9). Conse-
quently, the LIMA-LAD graft is associated with long-
term patency rates reaching 98% at 10 years (10,11).
Furthermore, a LIMA graft protects the native coro-
nary tree from the deleterious effects of disease pro-
gression (9).
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VEIN GRAFT PATENCY VERSUS STENT RESTE-
NOSIS AND THROMBOSIS: THE RATIONALE FOR
COMPLETING THE REVASCULARIZATION WITH
PCI. Unlike arterial conduits, veins were not
designed to bear the load of systemic
pressure; hence, venous grafts are more
prone to atherosclerotic degeneration and
progressive narrowing with high early and
long-term failure rates. In the ex vivo
PREVENT IV (Vein graft Engineering via
Transfection IV) study (12), angiographic
midterm (1 to 1.5 years) saphenous
vein graft (SVG) failure, deﬁned as
stenosis $75%, stood as high as 46%,
whereas reported graft occlusion rates in
the literature range from 6.2% to 32%
at 1 year (averaging w20%) (13–17), 29%
at 10 years, and 68% at 15 years (10) post-coronary
artery bypass graft surgery (CABG).
Newer drug-eluting stent (DES) platforms with
(e.g., everolimus-eluting stents [EES] or zotarolimus-
eluting stents [ZES]) or without (bioresorbable
polymer-based or polymer-free stents) durable poly-
mers show favorable outcomes, with 1-year target
lesion revascularization (TLR) rates as low as 3% to
3.25% (7) and midterm binary ($50%) restenosis rates
of 2.3% for EES (8 months) (18) and 3.1% for the
amphilimus-eluting, polymer-free stent (6 months)
(19). Even in high-risk patients and complex lesions,
ZES and EES maintain very low 1-year TLR rates of
4.4% and 4%, respectively (20). Thus, PCI and stent-
ing provide strong competition for SVG revasculari-
zation because, unlike an LIMA-LAD graft, disease
progression in the proximal native coronary segment
occurs alongside SVG deterioration.
Moreover, signiﬁcant angiographic SVG stenosis
occurs at least twice as frequently as binary in-stent
restenosis using the latest technology platforms.
However, ischemia-driven revascularization rates
are considerably higher in stented patients with
treated multivessel CAD (21). Furthermore, even
though SVG occlusion occurs at a higher rate com-
pared with stent thrombosis (10), the clinical conse-
quences of the latter are more dramatic, as it is more
frequently associated with major adverse clinical
events (MACE) (22).
PATIENT SELECTION FOR HCR
The role of the heart team in guiding appropriate
patient selection for HCR is crucial (23). In our view,
an important anatomical feature favoring HCR should
be plaque burden in the proximal LAD well charac-
terized by the SYNTAX (SYNergy Between PCI With
TAXUS and Cardiac Surgery) score (24). The classic
indication for HCR is multivessel CAD including: 1) a
proximal complex LAD lesion with optimal distal
anatomy amenable to LIMA-to-LAD grafting; 2) non-
LAD lesions amenable to PCI, in a patient with no
contraindications to dual antiplatelet therapy (DAPT);
and 3) a high likelihood of achieving “reasonable
incomplete revascularization” (25,26) with such an
approach.
Complex distal left main lesions are also ideal for
HCR if the circumﬂex artery territory is amenable for
PCI. HCR appears particularly appealing for patients
with the aforementioned coronary anatomy and
others considered too high risk for open cardiopul-
monary bypass surgery via midline sternotomy,
including those with a high risk of deep sternal
wound infection (e.g., diabetics, morbidly obese) (26),
severely impaired left ventricular function, chronic
kidney disease, signiﬁcant carotid or neurological
disease, severe aortic calciﬁcation, prior sternotomy,
and lack of venous conduits. The 2011 American
College of Cardiology Foundation/American Heart
Association guidelines for CABG state that the “pri-
mary purpose of performing HCR is to decrease the
morbidity rate of traditional CABG in high-risk pa-
tients” (27). Even in the more recent European Society
of Cardiology/European Association for Cardio-
Thoracic Surgery guidelines on myocardial revascu-
larization (28), HCR has a Class IIb recommendation
for speciﬁc patient subsets and only at experienced
centers. The lack of several large randomized con-
trolled trials (RCTs) involving different risk groups,
hinders the identiﬁcation of an HCR target group.
Consequently, physicians and surgeons do not
embrace HCR in routine clinical practice. In a recent
study from the Society of Thoracic Surgeons (STS)
Adult Cardiac Surgery Database (29), HCR represented
just 0.48% (n ¼ 950 patients) of the total CABG volume
(n ¼ 198,622) between July 2011 and March 2013.
TECHNICAL ISSUES
1- VERSUS 2-STAGED APPROACH. HCR can be per-
formed either simultaneously or as a “2-staged” pro-
cedure. The former implies concurrent CABG and PCI
in a single operative suite, with PCI following CABG
within minutes. In the “2-staged” approach, the
optimal order—PCI ﬁrst versus CABG ﬁrst—is debated
because each approach has advantages and disad-
vantages (Central Illustration). Currently, decisions
should be guided by patient characteristics, operator
skill/expertise, and available facilities.
A simultaneous approach is only feasible in
hybrid suites featuring state-of-the-art surgical and
ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery bypass
graft surgery
DES = drug-eluting stent(s)
HCR = hybrid coronary
revascularization
LAD = left anterior descending
artery
LIMA = left internal mammary
artery
MIDCAB = minimally invasive
direct coronary artery bypass
grafting
PCI = percutaneous coronary
intervention
SVG = saphenous vein graft
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interventional equipment. Often, CABG is performed
ﬁrst, allowing the interventional cardiologist to study
the LIMA-LAD graft before stent implantation. Thus,
PCI to high-risk, non-LAD lesions is performed with a
protected LAD territory. In case of unsuccessful stent
implantation, surgical bailout graft implantation re-
mains an option. Additionally, the simultaneous HCR
approach can be cost effective by reducing hospital
length of stay (30,31), the risk of lesion destabiliza-
tion, and recurrent hospital admissions between
staged procedures. An additional advantage: im-
proved patient satisfaction (30), as it condenses
revascularization into 1 patient encounter (27).
As for the limitations of this approach, 1 challenge
is balancing the need for appropriate antiplatelet
therapy, to avoid stent thrombosis, with surgical
bleeding risk. Performing the LIMA-LAD anastomosis
under DAPT can be difﬁcult, particularly when a
minimally invasive approach and video-assisted
LIMA take-down are used. Furthermore, the re-
sponse of DES to protamine administration at the
end of CABG has not been fully investigated
(32). When DAPT is not administered to reduce sur-
gical bleeding risk, PCI becomes risky and is not rec-
ommended. Another challenging scenario for “1-stop”
HCR is the patient with chronic kidney disease, who
is exposed in a short period of time to the dual
nephrotoxic insult of surgery and contrast media.
When the heart team favors a 2-step procedure,
the sequence of PCI and CABG should be guided
by clinical presentation and coronary anatomy.
In general, the American College of Cardiology
Foundation/American Heart Association guidelines
favor performing CABG ﬁrst (27). This strategy
CENTRAL ILLUSTRATION Advantages and Disadvantages of Simultaneous and Staged HCR Procedures
PCI 1st, then MID-CABMID-CAB 1st, then PCIMID-CAB followed by PCI within minutes
ONE STAGE (SIMULTANEOUS)
Advantages
•  LIMA-LAD graft can be studied by the 
interventional cardiologist before PCI
stent implantation
•  PCI to high-risk non-LAD lesions can be 
performed with a protected LAD area
•  In cases of unsuccessful stent 
implantation, conventional CABG 
remains an option
•  Cost effective, as it reduces hospital
length of stay (single-step complete 
revascularization)
•  Patient satisfaction: condenses 
revascularization therapy in one 
patient encounter
Disadvantages
•  Only feasible in hybrid suites, featuring 
state-of-the-art surgical and 
interventional equipment
•  Inflammatory response to surgery 
offers a risk for stent thrombosis
•  Dual antiplatelet therapy increases
the risk of bleeding
•  Chronic kidney disease patients are 
exposed to the dual nephrotoxic insult 
of surgery and contrast media 
utilization
Disadvantages
•  Risk of ischemia of non-LAD 
territories during the LIMA-LAD 
grafting (although this is very 
unlikely in stable patients)
•  Risk of a high-risk surgical
reintervention in case of an 
unsuccessful PCI
Disadvantages
•  No angiographic control of 
LIMA-LAD graft
•  Higher risk of stent thrombosis during 
surgery (due to inflammatory response
to surgery/discontinuation of dual 
antiplatelet therapy/platelet transfusion)
•  Increased perioperative bleeding
risk due to dual antiplatelet therapy 
during surgery
•  Risk of adverse events in the LAD 
territory during the between-
stages interval
Advantages
•  Allows angiographic validation of
the LIMA-LAD graft
•  Full antiplatelet inhibition following 
CABG with no perioperative 
bleeding risk
•  Protected anterior wall, lowering 
procedural risks during PCI of
non-LAD vessels
•  On some occasions, after minimally
invasive LIMA to LAD, patients 
become asymptomatic in the 
immediate post-operative period
Advantages
•  Allows angiographic evaluation of the 
size of LIMA
•  Lower risk of ischemia during the 
MID-CAB in a partially revascularized 
heart
•  Useful in the setting of acute 
myocardial infarction when culprit is a 
non-LAD lesion
•  In cases of unsuccessful stent 
implantation, suboptimal CABG can be
performed
Panoulas, V.F. et al. J Am Coll Cardiol. 2015; 65(1):85–97.
TWO-STAGE HCR
CABG ¼ coronary artery bypass grafting; HCR ¼ hybrid coronary revascularization; LAD ¼ left anterior descending artery; LIMA ¼ left internal
mammary artery; MI ¼ myocardial infarction; MID-CAB ¼ minimally invasive direct coronary artery bypass grafting; PCI ¼ percutaneous
coronary intervention.
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allows angiographic visualization of the LIMA-LAD
graft, facilitates full antiplatelet inhibition fol-
lowing CABG with no perioperative bleeding risk,
and provides a protected anterior wall, lowering
procedural risks during PCI of non-LAD vessels.
On some occasions after minimally invasive LIMA to
LAD, patients become asymptomatic in the
immediate post-operative period. In these cases,
particularly when the residual non-LAD lesions
are angiographically intermediate, optimal medical
therapy and watchful waiting may be in the
patients’ best interest (33).
The disadvantages of a CABG-ﬁrst approach
include the risk of ischemia of non-LAD territories
during the LIMA-LAD grafting (although highly un-
likely in stable patients) and the potential for a high-
risk surgical reintervention following unsuccessful
PCI. Although the PCI-ﬁrst strategy overcomes these
limitations, its disadvantages include a higher risk of
stent thrombosis (with discontinuations of DAPT,
administration of plasma/platelet products in case of
surgical bleeding, and the inﬂammatory response to
surgery), increased perioperative bleeding risk (with
optimal platelet inhibition), and risk of adverse
events in the LAD territory in the between-stages
interval. A PCI-ﬁrst approach does not allow angio-
graphic validation of the “prognostic” LIMA-LAD
graft and is not ideal in high-risk patients requiring
extensive non-LAD percutaneous revascularization.
However, a PCI-ﬁrst approach is reasonable in pa-
tients presenting with acute coronary syndrome
(ACS) who undergo non-LAD culprit lesion PCI fol-
lowed by CABG of the LAD. If the lesions treated with
PCI were the culprit ones, CABG can be delayed,
allowing safe discontinuation of DAPT. A PCI-ﬁrst
approach also allows angiographic evaluation of the
LIMA’s size.
ANTIPLATELET MANAGEMENT. One big challenge of
HCR: balancing the risk of perioperative bleeding
with that of stent thrombosis. In the majority of
HCR registries following the “CABG-ﬁrst” approach
(33–35), CABG was performed on aspirin; a second
antiplatelet agent was started >4 h post-bypass
after ensuring that no bleeding complications had
occurred. In the “PCI-ﬁrst” approach, DAPT is typi-
cally commenced ahead of the PCI procedure and is
continued uninterrupted during CABG (34). In most
series of simultaneous HCR, patients are not pre-
medicated with clopidogrel and undergo the LIMA-
LAD graft taking only aspirin, followed by a single
loading dose of clopidogrel 300 mg either when the
LIMA-LAD graft is completed (36), just before its
completion (37), or immediately post-PCI (30,38,39).
Another approach involves a loading dose of
clopidogrel at the induction of anesthesia (40) or
intraoperatively (35), because maximal platelet in-
hibition occurs 4 to 24 h after administration (41,42),
allowing the surgical step of simultaneous HCR to be
performed with acceptable bleeding risk. In some
registries, the exact timing and dose of antiplatelet
therapy during the “2-step” and simultaneous HCR
are not clearly described, highlighting the need for
more robust clinical guidance (43,44). Newer anti-
platelet agents like prasugrel, ticagrelor, or cangrelor
(45) (an investigational agent with rapid onset and
reversal) could prove to be safer alternatives for
HCR; however, this remains an “evidence-free”
zone.
THE INDIVIDUAL COMPONENTS OF HCR
THE LIMA-LAD ANASTOMOSIS. In most cases, the
LIMA-LAD anastomosis can be performed using the
minimally invasive approach, which aims to avoid
cardiopulmonary bypass and the sternotomy incision.
Minimally invasive direct coronary artery bypass
grafting (MIDCAB) is performed on the beating heart
through a small, left-sided thoracotomy in the 4th/
5th interspace via direct visualization. To avoid the
signiﬁcant chest wall manipulation associated with
MIDCAB and to improve post-operative pain control,
thoracoscopic and robotic techniques have been
developed. These include the endoscopic atraumatic
coronary artery bypass (Endo-ACAB), which allows
thoracoscopic/robotic LIMA identiﬁcation and mobi-
lization followed by a direct non–rib spreading tho-
racotomy permitting hand-sewn anastomosis on the
beating heart (46), and the totally endoscopic coro-
nary artery bypass grafting either on- or off-pump,
in which the anastomosis is performed intra-
corporeally using a robot. The latter, although
challenging, produces a reported clinical freedom
from graft failure as high as 98.6% at 13 months in
experienced hands (47).
WHICH TYPE OF STENT TO IMPLANT? Without
question, modern PCI should be performed with
second- or third-generation DES (7,48,49). Irre-
spective of DES choice, it is essential that DAPT be
continued for at least 6 months (50,51). Fully biode-
gradable DES are an interesting new development
(52,53), but long-term follow-up data, especially in
complex lesions, are needed before we consider them
a replacement for current metallic DES.
THE EVIDENCE ON HCR
Since the ﬁrst report in 1996 (1), there have been
multiple publications on single-center experiences
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TABLE 1 HCR Registries Published Since 2008
First Author,
Year (Ref. #)
Registry
Recruitment
HCR/Total
Assessed
(N ¼ 998)*
Age,
yrs
Male,
%
Diabetes,
%
LVEF,
%
ACS,
% Timing
SYNTAX
Score Risk Score
Surgical
Technique
Conversion
to Open
Angiographic
Type/Location
of PCI Lesions DES/BMS
Type of
DES
Adams et al.,
2013 (37)
2004–2012 94-96 64  12 72.9 N/A N/A 38 (UA) 1-stop N/A N/A MIDCAB
Da Vinci-OP
2 N/A 95/10 stents 91 PES
3 SES
1 ZES
Halkos et al.,
2013 (33)
2003–2012 269-300 64.12  12.1 68.3 36.7 54.7  69.2 34 (MI) 21 1-stop
192 CABG 1st
56 PCI 1st
1.6  2.1 (S) <2,009 Endo-
ACAB
>2,009MIDCAB
Da Vinci-OP
6 N/A 232/28 patients
28 DES þ BMS
4 POBA
3 Unknown
N/A
Repossini et al.,
2013 (43)
2004–2011 166 65.8  10.3 90.4 24.1 9.6 (EF <30%) 58.4 60 CABG 1st
106 PCI 1st
29.3  7.37 3.49  4.77 (EII)
4.69  3.77 (S)
MIDCAB-OP 4 N/A 57/109 patients N/A
Bonatti et al.,
2012 (35)
N/A 140-162 61 (31–85) 79.3 28.6 60 (20–79) 43.6 (MI) 28 1-stop
74 CABG 1st
38 PCI 1st
N/A 2 (0–13) (Add E)
0.5 (0.2–9.9) (S)
Robotic TECAB
On & off pump
22 N/A 98/34 patients
5 patients POBA
3 patients
aspiration
N/A
Rab et al.,
2012 (57)
N/A 22 61.0  13.7 59.1 27.3 54.8  8.8 N/A 22 CABG 1st 22.3  10.0 1.6  1.9 (S) MIDCAB
Da Vinci-OP
NA N/A 21/1 patients N/A
Bonaros et al.,
2011 (61)
2001–2009 130 58 (41–75) 77 N/A N/A N/A 21 1-stop
97 CABG 1st
12 PCI 1st
N/A NA OP MIDCAB (3)
AH-TECAB (96)
BH-TECAB (31)
13 N/A N/A N/A
Holzhey et al.,
2008 (44)
1996–2007 117 64.6  12.3 83.8 24.8 59.2  13.1 4.3 (UA) 5 1-stop
59 CABG 1st
53 PCI 1st
N/A 4.3 (Log E) MIDCAB (107)
OP TECAB (8)
TECAB (2)
N/A N/A N/A N/A
Kiaii et al.,
2008 (38)
2004–2007 58-60 59.9  11.7 78 23 N/A 17 (MI) 58 1-stop N/A N/A Endo-ACAB OP 2 A/B1: 31
B2/C: 28
53/6 stents 49 PES
3 SES
6 BMS
Values are mean  SD, median (interquartile range), n, or % as indicated. *If a single number, this indicates patients undergoing HCR.
ACS ¼ acute coronary syndrome(s); ACAB ¼ atraumatic coronary artery bypass; Add ¼ additive; AH ¼ arrested heart; BH ¼ beating heart; BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass graft surgery; DES ¼ drug-eluting stent(s); E ¼ EuroSCORE;
EF ¼ ejection fraction; Endo-ACAB ¼ endoscopic atraumatic coronary artery bypass; HCR ¼ hybrid coronary revascularization; Log ¼ logistic; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; MIDCAB ¼ minimally invasive direct coronary artery
bypass grafting; N/A ¼ not available; OP ¼ off pump; PES ¼ paclitaxel eluting stent(s); PCI ¼ percutaneous coronary intervention; POBA ¼ plain old balloon angioplasty; S ¼ Society of Thoracic Surgeons score; SES ¼ sirolimus-eluting stent(s); SYNTAX ¼ SYNergy
Between PCI With TAXUS and Cardiac Surgery; TECAB ¼ totally endoscopic coronary artery bypass grafting; UA ¼ unstable angina; ZES ¼ zotarolimus-eluting stent(s).
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TABLE 2 Cohorts Comparing HCR With Conventional On- or Off-Pump CABG Published Since 2008
First Author,
Year (Ref. #) HCR*
Age,
yrs
Male,
%
Diabetes,
%
LVEF,
%
ACS,
%
Timing
HCR SYNTAX Score Risk Score
Surgical
Technique
Conversion
to Open
Angiographic
Type/Location of
PCI Lesions DES/BMS
Type of DES
HCR Group
Shen et al., 2013 (36)
Retrospective, matched
cohort study (propensity
matched)
Recruitment: 2007–2010
141 HCR 62  9.9 88.7 26.2 62.7  7.1 N/A 1-stop 27.6  7.9 3.1  2.3 (Add E) MIDCAB N/A N/A 271/0 stents 210 SES
8 PES
12 E-ZES
41 R-ZES
141 CABG 62.4  7.8 90.1 18.4 62.6  8.0 N/A 28.2  9.4 3.3  2.3 (Add E) OP 20.6%
141 PCI 61.7  10.3 87.2 19.9 61.2  9.3 N/A 26.0  8.2 3.5  2.6 (Add E)
Leacche et al., 2013 (56)
Retrospective cohort study
(group stratiﬁcation)
Recruitment 2005–2009
80 HCR
SYNTAX#32
(67)
62 (32–85) 79 42 50 (20–70) 58 1-stop 4 (0–12) (Add E) OP 22% NA NA 62/7 patients NA
SYNTAX >32
(13)
74 (32–84) 62 31 50 (20–65) 61 6 (1–14) (Add E) OP 31% 10/3 patients
301 CABG
SYNTAX#32
(226)
63 (32–89) 75 38 55 (10–80) 71 4 (0–14) (Add E) OP 15%
SYNTAX >32
(75)
62 (32–83) 83 32 50 (10–70) 57 4 (0–15) (Add E) OP 16%
Bachinsky et al., 2012 (31)
Prospective cohort study,
no matching
Recruitment: 2009–2011
25 HCR 63.2  10.5 80† 36 55.3  10.4 32 1-stop 33.52  8 0.46  0.24 (S)† MIDCAB
(OP-Da Vinci)
100%
N/A A: 14% (n ¼ 6)
B1: 26% (n ¼ 11)
B2: 50% (n ¼ 21)
C: 10% (n ¼ 4)
42/18 stents 42 EES
18 BMS
27 OPCAB 66.78  10.7 59† 48 51.48  12.0 37 34.89  8.2 0.96  0.93 (S)†
Halkos et al., 2011 (34)
Retrospective matched
cohort study (propensity
matching)
Recruitment: 2003–2010
147 HCR 64.3  12.8 38.1† 39.5 54.7  8.7 13.6 MI N/A N/A 0.02  0.023 (S) EndoACAB N/A N/A N/A N/A
588 CABG 64.3  12.5 28.6† 35.5 54.6  8.7 12.4 MI N/A 0.018  0.021 (S) MIDCAB
(OP-Da Vinci)
Vassiliades et al., 2009
(46)
Retrospective cohort study
(no matching, propensity
score adjustment)
Recruitment: 2003–2007
91 HCR 64.7  13.7 76.3 40.7 51.5  9.4 18.7† 85 CABG 1st
6 PCI 1st
N/A N/A Endo-ACAB
MIDCAB
2 N/A 109/18 stents
1 POBA
NA
4,175 OPCAB 62.8  11.7 69.1 37.3 50.9  12.7 36.2† N/A NA OP 100%
Zhao et al., 2009 (40)
Retrospective cohort study
(no matching)
Recruitment: 2005–2007
112 HCR 63 (32–85) 71 39 50 (15–70) 74 1-stop N/A N/A OP open† 20% N/A N/A 95/9 patients
8 both
N/A
254 CABG 63 (32–89) 76 39 54 (10–72) 68 OP open 6.7%
Kon et al., 2008 (30)
Matched prospective cohort
study (unclear matching
method)
Recruitment: 2005–2006
15 HCR 61  10 73 27 47  14 N/A 1-stop N/A N/A MIDCAB OP N/A N/A 22/0 stents 11 PES
11 SES
30 OPCAB 65  10 63 40 45  14 N/A N/A N/A OP -open
Reicher et al., 2008 (39)
Prospective, matched
cohort study (propensity
matching)
2005–2006
13 HCR 62  10 80 29 31 (EF <40%) 0 CABG 1st N/A N/A OP MIDCAB 0 C: 77% 22/0 stents 11 SES
11 PES
26 CABG 64  10 83 41 27 (EF <40%) N/A N/A N/A OP open
Values are mean  SD, median (interquartile range), n, or % as indicated. *If single number, this indicates patients undergoing HCR. †Statistically signiﬁcant difference between the 2 groups (p < 0.05).
EES ¼ everolimus-eluting stent(s); E-ZES ¼ Endeavor zotarolimus-eluting stent(s); OP ¼ off-pump coronary artery bypass; R-ZES ¼ Resolute zotarolimus-eluting stent(s); other abbreviations as in Table 1.
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using HCR, with a cumulative population of >3,000
patients (54), one-third of whom were included
in registries published in the last 5 years (Table 1).
In this time period (2008 to 2013), 624 patients
who underwent HCR have been incorporated in
purposefully designed cohorts comparing their out-
comes with those from matched patients undergoing
conventional CABG (Table 2). In a recent meta-
analysis by Harskamp et al. (55) comprising 1,190
patients (1 case control and 5 propensity-matched
studies), no signiﬁcant differences were found for
the composite of death, myocardial infarction,
stroke, or repeat revascularization at 1 year (hazard
ratio: 0.49; 95% conﬁdence interval: 0.2 to 1.24;
p ¼ 0.13).
In the most recent registries (Table 1), CABG was
performed before PCI in about one-half of the HCR
procedures (50.6%; 504 of 996), whereas PCI was
performed ﬁrst in 26.6% (265 of 996). One-stop HCR
proved the least popular (22.8%; 227 of 996), high-
lighting the practical difﬁculties of setting up and
running a hybrid operating room. However, among
cohort studies (Table 2) comparing HCR with con-
ventional CABG, 1-stop HCR appears to be the most
popular strategy, highlighting that the simultaneous
approach is considered the gold standard for com-
parisons with other revascularization strategies. The
majority of HCR patients are just over 60 years of
age, are predominantly male (w70% to 80%), and
have a diabetes prevalence varying from 23% to
40.7% (Tables 1 and 2). The presentation mode varied
across the studies, with ACS prevalence as low as 0%
(39) or 13.6% (34) to as high as 74% (40). In the ma-
jority of HCR cases, left ventricular ejection fraction
was preserved or, at most, mildly impaired.
Most studies reported an average risk, using addi-
tive EuroSCORE, of 3.1 (36) to 6 (56), whereas STS
score was as low as 0.018% (34) to 4.69% (43). SYN-
TAX score, in the few studies reporting it, varied
from 22.3 (57) to 33.5 (31), suggesting that most
patients recruited in HCR registries and cohorts
belong to the intermediate SYNTAX group.
Perioperative HCR mortality ranged from 0%
(30,37–39) to 2.6% (40) with the exception of the high
SYNTAX-HCR group (n ¼ 13; median additive Euro-
SCORE of 6) in the study by Leacche et al. (56) with
a perioperative mortality of 23% (3 of 13). Most re-
ports focus on the lower morbidity related to the
minimally invasive nature of the procedure’s surgical
component as compared with conventional CABG.
Low morbidity is mirrored by reduced blood trans-
fusion requirements (31,34,36), shorter intensive care
and hospital length of stay, and faster recovery
(30,31,39,58).
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Among HCR cohorts, excellent LIMA patency rates
have been reported at various intervals from grafting.
Fitzgibbon A or B LIMA patency rates (A [excellent],
B [fair], or O [occluded]) (59) have been reported in
a high percentage of patients: ranging from 93% to
100% (31,33,40,43,46,57) of patients in the perioper-
ative period (on the day of surgery or pre-discharge);
90% (39) and 94% (37) of patients at 6 months; 100%
(30) at 1 year; and 91% (38) of HCR patients at 2 years
post-grafting. Only 2 studies in the last 5 years re-
ported angiographic follow-up of patients who un-
derwent HCR. In a study of 60 patients, Kiaii et al.
(38) reported 2-year angiographic follow up in 54
(90%) patients. Binary in-stent restenosis rates were
13%, whereas in-stent thrombosis was observed in
3.7% of patients. In another study of 94 HCR patients
with 6-month angiographic follow-up (37), binary in-
stent restenosis was reported in 9% of patients,
whereas in-stent thrombosis was seen in 2.2%. These
ﬁgures concur with those reported from studies
using ﬁrst-generation DES (7).
Follow-up data from HCR registries (Table 3)
demonstrate survival rates of 92.5% (44) to 100%
(37) at 1 year and 84.8% (44) to 93% (43) at 5 years.
MACE-free survival varied from 83.9% (35) to 93.1%
(43) at 1 year down to 75.2% (35) to 83% (43) at 5
years. When pooling the results from 2 retrospective
cohort studies comparing long-term survival and
MACE between propensity-matched patients under-
going conventional CABG or HCR (34,36), similar
mortality rates (at 3 to 5 years) were observed
(Figure 1A). However, at 3 years, HCR patients
experienced an increased rate of repeat revasculari-
zation (hazard ratio: 3.17; 95% conﬁdence interval:
1.74 to 5.79) (Figure 1B). Of note, patients recruited
in both studies had relatively low surgical risk
calculated with additive EuroSCORE and STS. Leac-
che et al. (56) attempted to assess 30-day outcomes
in HCR versus standard CABG after stratiﬁcation
for risk score (EuroSCORE) and disease complexity
(SYNTAX score). They concluded that even though
HCR may be a safe alternative in patients with less
complex disease (SYNTAX score #32), CABG should
be the preferred strategy in those with SYNTAX
score >32 as survival (100% vs. 77%; p ¼ 0.003) and
MACE (5% vs. 30%; p ¼ 0.015) favored standard
FIGURE 1 Long-Term Mortality and Revascularization Rates in HCR Patients
Halkos M et al. 2011
Shen L et al. 2013
Total (95% CI)
Total events
Heterogeneity: Chi2= 0.57, df= 1 (P = 0.45); I2= 0%
Test for overall effect: Z= 1.07 (P = 0.28)
Halkos M et al. 2011
Shen L et al. 2013
Total (95% CI)
Total events
Heterogeneity: Chi2= 0.51, df= 1 (P = 0.47); I2= 0%
Test for overall effect: Z= 3.76 (P = 0.0002)
0.01 0.1 1 10 100
Favors HCR
0.01 0.1 1 10 100
Favors HCR
0.80 [0.09, 6.89]
0.24 [0.03, 2.22]
0.43 [0.09, 2.01]
33.3%
66.7%
100.0%
588
141
729
5
4
9
147
141
288
1
1
2
Odds Ratio
M-H, Fixed, 95% CI
Odds Ratio
M-H, Fixed, 95% CI
Odds Ratio
M-H, Fixed, 95% CI
Odds Ratio
M-H, Fixed, 95% CI
CABGHCR
CABGHCR
Study or Subgroup
Study or Subgroup
Events
Events Events
Total
Total Total
TotalEvents weight
weight
18
6
24
147
141
288
22
3
25
588
141
729
72.9%
27.1%
100.0%
3.59 [1.87, 6.89]
2.04 [0.50, 8.34]
3.17 [1.74, 5.79]
Any revascularization (3 years)
All-cause mortality (3-5 years)A
B
Favors CABG
Favors CABG
Pooled results from the only 2 propensity-matched cohort studies comparing hybrid coronary revascularization (HCR) versus coronary artery
bypass grafting (CABG) surgery available in the literature (search in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled trials
from 2008 through December 2013) demonstrate similar long-term mortality (A) but increased revascularization rate (B) in patients under-
going HCR. In the absence of signiﬁcant statistical heterogeneity (I2), a ﬁxed effects model was used. CI ¼ conﬁdence interval; M-H ¼ Mantel-
Haenszel.
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TABLE 4 Cohort Studies Comparing Angiographic and Clinical Follow-Up in Patients Undergoing HCR Versus CABG
Angiographic Follow-Up In-Hospital Outcomes Clinical Follow-Up
First Author,
Year (Ref. #) N Follow-Up
Number of
Patients in
Follow-Up
% LIMA
Patency
Fitzgibbon
A/B
ISR
>50%,
%
IST
(Occlusion),
%
Perioperative
Mortality,
%
Blood
Transfusion,
% ICU LOS
Hospital LOS,
Days
Survival, %
(Follow-Up Time)
Event-Free
Survival, %
(Follow-Up Time)
Revascularization, %
(Follow-Up Time)
Shen et al., 2013 (36)
Retrospective, matched
cohort study (propensity
matched)
Recruitment: 2007–2010
141 HCR N/A N/A N/A N/A N/A N/A 21.3* N/A 8.19  2.54 99.3 (3 yrs) 93.6 (3 yrs)* 6 (3 yrs)*
141 CABG N/A N/A N/A N/A N/A 31.9* N/A 8.49  3.53 97.2 (3 yrs) 86.5 (3 yrs)* 3 (3 yrs)*
141 PCI N/A N/A N/A N/A N/A N/A N/A N/A N/A 96.5 (3 yrs) 77.3 (3 yrs)* 18 (3 yrs)*
Leacche et al., 2013 (56)
Retrospective cohort study
(group stratiﬁcation)
Recruitment: 2005–2009
80 HCR
SYNTAX #32
(67)
N/A N/A N/A N/A N/A 1 18 N/A N/A 99 (30 days) 96 (30 days) N/A
SYNTAX >32
(13)
23* 31 77 (30 days)* 70 (30 days)*
301 CABG
SYNTAX #32
(226)
N/A N/A N/A N/A N/A 2 17 N/A N/A 98 (30 days) 93 (30 days) N/A
SYNTAX >32
(75)
0* 3 100 (30 days)* 95 (30 days)*
Bachinsky et al., 2012 (31)
Prospective cohort study,
no matching
Recruitment: 2009–2011
25 HCR On the
table
24 96 (A) N/A N/A N/A 12* 28.5  13.9 h 5.1  2.8* 100 (30 days) 100 (30 days) 0 (30 days)
27 OPCAB N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 96 (30 days) 0 (30 days)
Halkos et al., 2011 (34)
Retrospective matched
cohort study (propensity
matching)
Recruitment: 2003–2010
147 HCR N/A N/A N/A N/A N/A 0.7 35.4* 52.7  87.8 h 6.1  4.7 86.8 (5 yrs) 98 (on discharge) 12.2 (3.2 yrs)*
588 OPCAB N/A N/A N/A N/A N/A 0.9 56* 57.4  145.0 h 6.6  6.7 84.3 (5 yrs) 98 (on discharge) 3.7 (3.2 yrs)*
Vassiliades et al., 2009 (46)
Retrospective cohort study (no
matching, propensity score
adjustment)
Recruitment: 2003–2007
91 HCR Prior to
discharge
91 100 N/A N/A N/A 20.9 NA 4.2  2.5 98.9 (1 yr)
96.9 (2 yrs)
94 (3 yrs)
96.7 (30 days)
90 (1 yr)
0 (30 days)
5.5 (1 yr)
4,175 OPCAB N/A N/A N/A N/A N/A N/A N/A N/A N/A 94.5 (1 yr)
91.8 (2 yrs)
89.2 (3 yr)
97 (30 days)
N/A (1 yr)
0.3 (30 days)
N/A (1 yr)
Zhao et al., 2009 (40)
Retrospective cohort study
(no matching)
Recruitment: 2005–2007
112 HCR On the
table
366 93 N/A 0.3 2.6 N/A N/A 6 (1–97) N/A N/A N/A
254 CABG 1.5 N/A N/A 5 (1–33) N/A N/A N/A
Kon et al., 2008 (30)
Matched prospective
cohort study (unclear
matching method)
Recruitment: 2005–2006
15 HCR 1 yr 15 100 (HCR
only)
N/A N/A 0 N/A 0.98  0.42 days* 3.7  1.4* 100 (1 yr) 93 (1 yr) 3 (1 yr)
30 OPCAB 30 0 N/A 2.42  1.57 days* 6.4  2.2* 100 (1 yr) 77 (1 yr) 15 (1 yr)
Reicher et al., 2008 (39)
Prospective, matched cohort
study (propensity matching)
Recruitment: 2005–2006
13 HCR 6 months 10 90 N/A 10 0 N/A 20  2.4 h 3.6  1.5 * 0 (6 months) 84.6 (14 months) 15.4 (14 months)
26 CABG 0 N/A 44.5  36.4 h 6.3  2.3* 0 (6 months) 77.8 (14 months) 22.2 (14 months)
Values are mean  SD, median (interquartile range), n, or % as indicated. *Statistically signiﬁcant difference between the 2 groups (p < 0.05).
Abbreviations as in Tables 1, 2, and 3.
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surgery. However, these results may simply reﬂect
the effect of unadjusted confounders (increased age
by w8 years in the HCR group). In contrast, the
propensity-matched cohort from Shen et al. (36)
showed no difference in MACE rates between HCR
and CABG (p ¼ 0.362) in patients with high SYNTAX
scores ($30) (Table 4). Furthermore, the same study
showed that among patients with high additive
EuroSCORE ($6), those who underwent 1-stop HCR
demonstrated a signiﬁcantly lower MACE rate versus
CABG (p ¼ 0.030) (Figure 2). These data underscore
the importance of meticulous patient selection for
HCR procedures and support the hypothesis that
high-risk candidates may beneﬁt the most from
hybrid procedures.
The results of the ﬁrst RCT comparing HCR
(CABG ﬁrst) and standard CABG, POL-MIDES (Pro-
spective Randomized PilOt Study EvaLuating the
Safety and Efﬁcacy of Hybrid Revascularization
in MultIvessel Coronary Artery DisEaSe), were only
recently published (60). A total of 200 consecutive
patients with angiographically conﬁrmed multi-
vessel CAD involving the proximal LAD and a
signiﬁcant (>70%) lesion in at least 1 major non-
LAD epicardial vessel amenable to both PCI and
CABG were randomized in a 1:1 fashion to HCR
(n ¼ 98) (using MIDCAB and cobalt chromium
EES) or conventional CABG (n ¼ 102). Both groups
had similar baseline demographic characteristics,
risk factor proﬁles, and SYNTAX scores. HCR
was feasible for 93.9% of patients whereas conver-
sion to standard CABG was required for 6.1%. At
1 year, both groups had similar all-cause mortality
(CABG 2.9% vs. HCR 2%; p ¼ NS) and MACE-free
survival rates (CABG 92.2% vs. HCR 89.8%;
p log-rank ¼ 0.54).
Even though larger RCTs with long-term follow
up are needed before ﬁrm conclusions are drawn,
available data suggest that HCR is feasible and safe,
with short-term outcomes similar to conventional
FIGURE 2 Improved MACCE in HCR Group
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Improved major adverse cardiac and cerebrovascular events (MACCE) among patients in the HCR group versus conventional CABG and percutaneous coronary inter-
vention (PCI) in the high EuroSCORE tertile. Adapted with permission from Shen et al. (36). SYNTAX ¼ SYNergy Between PCI With TAXUS and Cardiac Surgery; other
abbreviations as in Figure 1.
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CABG in carefully selected, low- to intermediate-risk
patients with intermediate CAD complexity.
UNRESOLVED ISSUES
The burning question that prevents HCR from taking
off remains unanswered: why should institutes
adopt a complex, costly procedure requiring state-
of-the-art equipment, unique expertise, and close
collaboration of interventional cardiologists and car-
diac surgeons, when similar survival and morbidity
outcomes can be obtained with a well-established,
safe procedure available in most hospitals? First, a
recent well-designed (albeit retrospective) study (36),
shows signals of improved MACE outcomes in the
HCR versus conventional CABG group for patients
in the highest EuroSCORE tertile (>6), suggesting a
potential target population that would beneﬁt the
most from this complex procedure (Figure 1).
Second, the use of HCR in lower- to intermediate-
risk groups could be justiﬁed by improved patient
satisfaction (30,31), shorter intensive care and hos-
pital stays, faster return to work (HCR 1.75  1
month vs. CABG 4.4  3.1 months; p ¼ 0.01) (30),
and quicker return to normal daily activities. Con-
ventional CABG advocates would claim that HCR
is a more costly procedure, as demonstrated by
in-hospital cost-speciﬁc data (30,31,39) and hidden
costs involving construction and maintenance of
hybrid operating rooms. Health commissioners and
governments, however, may hold a different view
when taking into account the working days lost due
to delayed healing/recovery following conventional
CABG.
Another unresolved issue: the appropriateness of
HCR versus CABG comparisons without introducing
a third group of patients treated with PCI, including
new-generation DES implantation under fractional
ﬂow reserve guidance. Last, but not least, for patients
who undergo LIMA to LAD ﬁrst as part of an intended
staged HCR, and who become asymptomatic post-
procedure, the beneﬁts of PCI to residual inter-
mediate non-LAD lesions should be questioned.
Optimal medical therapy—watchful waiting alongside
ischemia testing when symptomatology is unclear—
provides a reasonable alternative, albeit not evidence
based.
CONCLUSIONS
Current evidence suggests that HCR is feasible and
safe for a particular target group (just over 60 years
of age; mainly stable, CAD favorable anatomy; in-
termediate risk and SYNTAX scores; and preserved
or mildly impaired left ventricular ejection fraction)
with acceptable midterm outcomes that are non-
inferior to conventional CABG. However, data for
higher-risk groups, who would theoretically beneﬁt
the most from HCR, are weak or lacking; hence, no
inferences or generalizations can be made regarding
the role of HCR in these patients. It is now in the
hands of the scientiﬁc community and health man-
agers to identify patients who would beneﬁt the
most and ﬁnd ways to make HCR a cost-effective
procedure for both hospitals and societies. If these
goals are not achieved, HCR will remain a very
reasonable, yet rarely implemented, revasculariza-
tion option.
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